Trovagene,Inc. (NASDAQ:TROV) Files An 8-K Regulation FD DisclosureItem 7.01
Trovagene,Inc. intends to conduct meetings with third parties in which its corporate slide presentation will be presented.A copy of the presentation materials is attached as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.
The information in this Item 7.01 and the document attached as Exhibit99.1 are being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
| Item 7.01. | Financial Statements and Exhibits |
(d) Exhibits.
| 99.1 | Trovagene, Inc. Corporate Presentation |
-2-
Trovagene, Inc. ExhibitEX-99.1 2 d472809dex991.htm EX-99.1 EX-99.1 Using Our Precision Medicine Strategy to Develop Oncology Drugs That Target Mitosis July 2018 Exhibit 99.1 Forward-Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as “anticipate,…To view the full exhibit click here
About Trovagene,Inc. (NASDAQ:TROV)
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.
